{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:52:19Z","timestamp":1776898339970,"version":"3.51.2"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11060-026-05503-9","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:58:34Z","timestamp":1773241114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Individualized prediction of survival after brain metastasis development in patients with breast cancer"],"prefix":"10.1007","volume":"177","author":[{"given":"Gino","family":"Cioffi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Waite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ancha","family":"Baranova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Barnholtz-Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"5503_CR1","unstructured":"Cancer Facts and Figs (2025) (American Cancer Society, Atlanta."},{"key":"5503_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"5503_CR3","doi-asserted-by":"crossref","unstructured":"Park M et al (2022) Breast Cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci 23","DOI":"10.3390\/ijms23126806"},{"key":"5503_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-811161-1.00002-5","volume":"149","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Wright CH, Barnholtz-Sloan JS (2018) Brain metastases: epidemiology. Handb Clin Neurol 149:27\u201342","journal-title":"Handb Clin Neurol"},{"key":"5503_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y (2020) Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 5:28","journal-title":"Signal Transduct Target Ther"},{"key":"5503_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH et al (2020) Current approaches to the management of brain metastases. Nat Rev Clin Oncol 17:279\u2013299","journal-title":"Nat Rev Clin Oncol"},{"key":"5503_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast Cancer Treatment: A Review. JAMA 321:288\u2013300","journal-title":"JAMA"},{"key":"5503_CR8","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin NU et al (2020) Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol 38:2610\u20132619","journal-title":"J Clin Oncol"},{"key":"5503_CR9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S et al (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 382:610\u2013621","journal-title":"N Engl J Med"},{"key":"5503_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2217\/cns.15.5","volume":"4","author":"CA Castaneda","year":"2015","unstructured":"Castaneda CA et al (2015) Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer. CNS Oncol 4:137\u2013145","journal-title":"CNS Oncol"},{"key":"5503_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/cam4.439","volume":"4","author":"JP Leone","year":"2015","unstructured":"Leone JP, Lee AV, Brufsky AM (2015) Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med 4:989\u2013994","journal-title":"Cancer Med"},{"key":"5503_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.07.004","volume":"102","author":"I Witzel","year":"2018","unstructured":"Witzel I et al (2018) Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer 102:1\u20139","journal-title":"Eur J Cancer"},{"key":"5503_CR13","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.18632\/oncotarget.14047","volume":"8","author":"I Hohensee","year":"2017","unstructured":"Hohensee I et al (2017) PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression. Oncotarget 8:6155\u20136168","journal-title":"Oncotarget"},{"key":"5503_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:61","journal-title":"Breast Cancer Res"},{"key":"5503_CR15","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F et al (2018) Survival outcomes by TP53 mutation status in metastatic breast cancer. JCO Precis Oncol","DOI":"10.1200\/PO.17.00245"},{"key":"5503_CR16","doi-asserted-by":"crossref","unstructured":"Batalini F et al (2020) Response of brain metastases from PIK3CA-mutant breast cancer to alpelisib. JCO Precis Oncol 4","DOI":"10.1200\/PO.19.00403"},{"key":"5503_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41698-024-00761-0","volume":"8","author":"A Giannoudis","year":"2024","unstructured":"Giannoudis A et al (2024) Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors. NPJ Precis Oncol 8:282","journal-title":"NPJ Precis Oncol"},{"key":"5503_CR18","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","volume":"16","author":"VP Balachandran","year":"2015","unstructured":"Balachandran VP, Gonen M, Smith JJ, DeMatteo RP (2015) Nomograms in oncology: more than meets the eye. Lancet Oncol 16:e173\u2013180","journal-title":"Lancet Oncol"},{"key":"5503_CR19","first-page":"vdz007","volume":"1","author":"H Gittleman","year":"2019","unstructured":"Gittleman H et al (2019) An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival. Neurooncol Adv 1:vdz007","journal-title":"Neurooncol Adv"},{"key":"5503_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12876-024-03331-7","volume":"24","author":"B Huang","year":"2024","unstructured":"Huang B et al (2024) Development and validation of a nomogram based on Lasso-Logistic regression for predicting splenomegaly secondary to acute pancreatitis. BMC Gastroenterol 24:281","journal-title":"BMC Gastroenterol"},{"key":"5503_CR21","doi-asserted-by":"publisher","first-page":"105049","DOI":"10.1016\/j.ijmedinf.2023.105049","volume":"174","author":"W Xie","year":"2023","unstructured":"Xie W, Li Y, Meng X, Zhao M (2023) Machine learning prediction models and nomogram to predict the risk of in-hospital death for severe DKA: A clinical study based on MIMIC-IV, eICU databases, and a college hospital ICU. Int J Med Inf 174:105049","journal-title":"Int J Med Inf"},{"key":"5503_CR22","doi-asserted-by":"publisher","first-page":"714639","DOI":"10.3389\/fgene.2021.714639","volume":"12","author":"T Huang","year":"2021","unstructured":"Huang T, Yan T, Chen G, Zhang C (2021) Development and Validation of a Gene Mutation-Associated Nomogram for Hepatocellular Carcinoma Patients From Four Countries. Front Genet 12:714639","journal-title":"Front Genet"},{"key":"5503_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri F et al (2019) DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol 21:901\u2013910","journal-title":"Neuro Oncol"},{"key":"5503_CR24","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"APG Consortium","year":"2017","unstructured":"Consortium APG, AACR Project GENIE (2017) Powering Precision Medicine through an International Consortium. Cancer Discov 7:818\u2013831","journal-title":"Cancer Discov"},{"key":"5503_CR25","first-page":"e2100105","volume":"6","author":"JA Lavery","year":"2022","unstructured":"Lavery JA et al (2022) A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. JCO Clin Cancer Inf 6:e2100105","journal-title":"JCO Clin Cancer Inf"},{"key":"5503_CR26","unstructured":"Project AACR GENIE 16.0-public Data guide. (AACR)"},{"key":"5503_CR27","doi-asserted-by":"crossref","unstructured":"Lavery JA et al (2023) A data processing pipeline for the AACR project GENIE biopharma collaborative data with the genieBPC R package. Bioinformatics 39","DOI":"10.1093\/bioinformatics\/btac796"},{"key":"5503_CR28","unstructured":"Whiting K, Curry M, Fuchs H, Martin A, Arora A gnomeR: Wrangle and analyze IMPACT and TCGA mutation data"},{"key":"5503_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1158\/2767-9764.CRC-23-0409","volume":"4","author":"E Sanz-Garcia","year":"2024","unstructured":"Sanz-Garcia E et al (2024) Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry. Cancer Res Commun 4:475\u2013486","journal-title":"Cancer Res Commun"},{"key":"5503_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/pst.2202","volume":"21","author":"A Sondhi","year":"2022","unstructured":"Sondhi A (2022) Estimating survival parameters under conditionally independent left truncation. Pharm Stat 21:895\u2013906","journal-title":"Pharm Stat"},{"key":"5503_CR31","unstructured":"Friedman J et al (2023), CRAN,. glmnet: lasso and elastic-net regularized generalized linear models, version 4.1-8."},{"key":"5503_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/1740774518759281","volume":"15","author":"T Karrison","year":"2018","unstructured":"Karrison T, Kocherginsky M (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178\u2013188","journal-title":"Clin Trials"},{"key":"5503_CR33","unstructured":"Gerds TA et al (2023), riskRegression: risk regression models and prediction scores for survival analysis with competing risks."},{"key":"5503_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.21037\/atm.2018.07.38","volume":"6","author":"Z Zhang","year":"2018","unstructured":"Zhang Z et al (2018) Overview of model validation for survival regression model with competing risks using melanoma study data. Ann Transl Med 6:325","journal-title":"Ann Transl Med"},{"key":"5503_CR35","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1002\/sim.6152","volume":"33","author":"TA Gerds","year":"2014","unstructured":"Gerds TA, Andersen PK, Kattan MW (2014) Calibration plots for risk prediction models in the presence of competing risks. Stat Med 33:3191\u20133203","journal-title":"Stat Med"},{"key":"5503_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/bimj.200810443","volume":"50","author":"TA Gerds","year":"2008","unstructured":"Gerds TA, Cai T, Schumacher M (2008) The performance of risk prediction models. Biom J 50:457\u2013479","journal-title":"Biom J"},{"key":"5503_CR37","unstructured":"Harrell FE (2024) rms: regression modeling strategies"},{"key":"5503_CR38","unstructured":"Zhicheng D, Hao Y, (2017) NomogramEx: extract equations from a nomogram"},{"key":"5503_CR39","doi-asserted-by":"crossref","unstructured":"Tommasi C et al (2024) Hormone receptor-positive\/HER2-positive breast cancer: hormone therapy and anti-HER2 treatment: an update on treatment strategies. J Clin Med 13","DOI":"10.3390\/jcm13071873"},{"key":"5503_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS (2022) Pathogenesis of Triple-Negative Breast Cancer. Annu Rev Pathol 17:181\u2013204","journal-title":"Annu Rev Pathol"},{"key":"5503_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","volume":"27","author":"FM Howard","year":"2021","unstructured":"Howard FM, Olopade OI (2021) Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J 27:8\u201316","journal-title":"Cancer J"},{"key":"5503_CR42","doi-asserted-by":"publisher","first-page":"642677","DOI":"10.3389\/fonc.2021.642677","volume":"11","author":"Q Liu","year":"2021","unstructured":"Liu Q et al (2021) NCCBM, a Nomogram Prognostic Model in Breast Cancer Patients With Brain Metastasis. Front Oncol 11:642677","journal-title":"Front Oncol"},{"key":"5503_CR43","doi-asserted-by":"publisher","first-page":"759577","DOI":"10.3389\/fonc.2021.759577","volume":"11","author":"X Cheng","year":"2021","unstructured":"Cheng X, Zhao JX, Dong F, Cao XC (2021) ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target. Front Oncol 11:759577","journal-title":"Front Oncol"},{"key":"5503_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cpt.2453","volume":"111","author":"DR Rivera","year":"2022","unstructured":"Rivera DR et al (2022) The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. Clin Pharmacol Ther 111:283\u2013292","journal-title":"Clin Pharmacol Ther"},{"key":"5503_CR45","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdq429","volume":"22","author":"H Roche","year":"2011","unstructured":"Roche H, Vahdat LT (2011) Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 22:1000\u20131010","journal-title":"Ann Oncol"},{"key":"5503_CR46","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.ejca.2015.07.040","volume":"51","author":"VK Ho","year":"2015","unstructured":"Ho VK et al (2015) Survival of breast cancer patients with synchronous or metachronous central nervous system metastases. Eur J Cancer 51:2508\u20132516","journal-title":"Eur J Cancer"},{"key":"5503_CR47","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.clineuro.2013.07.030","volume":"115","author":"L Gerdan","year":"2013","unstructured":"Gerdan L et al (2013) The number of involved extracranial organs: a new predictor of survival in breast cancer patients with brain metastasis. Clin Neurol Neurosurg 115:2108\u20132110","journal-title":"Clin Neurol Neurosurg"},{"key":"5503_CR48","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R et al (2019) The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19:1091","journal-title":"BMC Cancer"},{"key":"5503_CR49","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/sj.bjc.6601038","volume":"89","author":"L Wyld","year":"2003","unstructured":"Wyld L et al (2003) Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 89:284\u2013290","journal-title":"Br J Cancer"},{"key":"5503_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10585-021-10080-4","volume":"38","author":"NS Rashid","year":"2021","unstructured":"Rashid NS, Grible JM, Clevenger CV, Harrell JC (2021) Breast cancer liver metastasis: current and future treatment approaches. Clin Exp Metastasis 38:263\u2013277","journal-title":"Clin Exp Metastasis"},{"key":"5503_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12885-021-07968-5","volume":"21","author":"L Ji","year":"2021","unstructured":"Ji L et al (2021) Risk and prognostic factors of breast cancer with liver metastases. BMC Cancer 21:238","journal-title":"BMC Cancer"},{"key":"5503_CR52","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1146\/annurev-biochem-082411-113907","volume":"83","author":"CA Worby","year":"2014","unstructured":"Worby CA, Dixon JE, Pten (2014) Annu Rev Biochem 83:641\u2013669","journal-title":"Annu Rev Biochem"},{"key":"5503_CR53","doi-asserted-by":"publisher","first-page":"895729","DOI":"10.3389\/fendo.2022.895729","volume":"13","author":"SA Jeffreys","year":"2022","unstructured":"Jeffreys SA et al (2022) Prognostic and Predictive Value of CCND1\/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 13:895729","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5503_CR54","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s12094-020-02481-w","volume":"23","author":"SN Aleksakhina","year":"2021","unstructured":"Aleksakhina SN et al (2021) CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer. Clin Transl Oncol 23:874\u2013881","journal-title":"Clin Transl Oncol"},{"key":"5503_CR55","doi-asserted-by":"crossref","unstructured":"Voskarides K, Giannopoulou N (2023) The role of TP53 in adaptation and evolution. Cells 12","DOI":"10.3390\/cells12030512"},{"key":"5503_CR56","first-page":"34","volume":"16","author":"J Huszno","year":"2018","unstructured":"Huszno J, Grzybowska E (2018) TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer. Oncol Lett 16:34\u201340","journal-title":"Oncol Lett"},{"key":"5503_CR57","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/2159-8290.CD-13-0136","volume":"4","author":"E Powell","year":"2014","unstructured":"Powell E, Piwnica-Worms D (2014) Piwnica-Worms, H. Contribution of p53 to metastasis. Cancer Discov 4:405\u2013414","journal-title":"Cancer Discov"},{"key":"5503_CR58","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3892\/or.2014.3346","volume":"32","author":"P Dobes","year":"2014","unstructured":"Dobes P et al (2014) Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. Oncol Rep 32:1695\u20131702","journal-title":"Oncol Rep"},{"key":"5503_CR59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jmedgenet-2015-103529","volume":"53","author":"DF Easton","year":"2016","unstructured":"Easton DF et al (2016) No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J Med Genet 53:298\u2013309","journal-title":"J Med Genet"},{"key":"5503_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clbc.2021.12.007","volume":"22","author":"EM Walsh","year":"2022","unstructured":"Walsh EM et al (2022) Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1\/2 Mutations or Mutations in Non-BRCA1\/2, DNA Damage Repair Genes. Clin Breast Cancer 22:319\u2013325","journal-title":"Clin Breast Cancer"},{"key":"5503_CR61","doi-asserted-by":"crossref","unstructured":"Nakamura K et al (2020) Olaparib monotherapy for BRIP1-mutated high-grade serous endometrial cancer. JCO Precis Oncol 4","DOI":"10.1200\/PO.19.00368"},{"key":"5503_CR62","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ygyno.2020.09.040","volume":"159","author":"MA Ciccone","year":"2020","unstructured":"Ciccone MA et al (2020) Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells. Gynecol Oncol 159:869\u2013876","journal-title":"Gynecol Oncol"},{"key":"5503_CR63","first-page":"215","volume":"15","author":"KN Dziadkowiec","year":"2016","unstructured":"Dziadkowiec KN, Gasiorowska E, Nowak-Markwitz E, Jankowska A (2016) PARP inhibitors: review of mechanisms of action and BRCA1\/2 mutation targeting. Prz Menopauzalny 15:215\u2013219","journal-title":"Prz Menopauzalny"},{"key":"5503_CR64","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1002\/cncr.26716","volume":"118","author":"NF Marko","year":"2012","unstructured":"Marko NF, Xu Z, Gao T, Kattan MW, Weil RJ (2012) Predicting survival in women with breast cancer and brain metastasis: a nomogram outperforms current survival prediction models. Cancer 118:3749\u20133757","journal-title":"Cancer"},{"key":"5503_CR65","first-page":"7090","volume":"15","author":"Z Huang","year":"2018","unstructured":"Huang Z et al (2018) A nomogram for predicting survival in patients with breast cancer brain metastasis. Oncol Lett 15:7090\u20137096","journal-title":"Oncol Lett"},{"key":"5503_CR66","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.03.020","volume":"114","author":"PW Sperduto","year":"2022","unstructured":"Sperduto PW et al (2022) Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. Int J Radiat Oncol Biol Phys 114:60\u201374","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05503-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:07:13Z","timestamp":1776074833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05503-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["5503"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05503-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AACR Project GENIE requires that each participating center share data in a manner consistent with patient consent and center-specific Institutional Review Board (IRB) policies. These policies consist of one of the following: IRB-approved patient-consent to sharing of de-identified data, captured at time of molecular testing; IRB waivers and; and IRB approvals of GENIE-specific research proposals. Additionally, all data has been de-identified via the HIPAA Safe Harbor Method.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}